Intensive chemotherapy is not recommended for patients aged >60 years who have myelodysplastic syndromes or acute myeloid leukemia with high-risk karyotypes

Cancer

Volumn 110, Issue 2, 2007, Pages 345-352

  Knipp, Sabine ^a   Hildebrand, Barbara ^a   Kündgen, Andrea ^a   Giagounidis, Aristoteles ^b   Kobbe, Guido ^a   Haas, Rainer ^a   Aul, Carlo ^b   Gattermann, Norbert ^a   Germing, Ulrich ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b ST JOHANNES HOSPITAL   (Germany)

Author keywords

Acute myeloid leukemia; Complex karyotype; Intensive chemotherapy; Myelodysplastic syndrome

Indexed keywords

AMPHOTERICIN B; ANTINEOPLASTIC AGENT; CIPROFLOXACIN; COLISTIN; COTRIMOXAZOLE; CYTARABINE; ETOPOSIDE; HYDROXYUREA; IDARUBICIN; TIOGUANINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGE; AGED; AGING; ARTICLE; CANCER CHEMOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CHROMOSOME 7; CHROMOSOME ANALYSIS; DRUG DOSE INCREASE; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; FEMALE; HIGH RISK POPULATION; HUMAN; KARYOTYPE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL TIME;

ACUTE DISEASE; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HUMANS; KARYOTYPING; LEUKEMIA, MYELOID; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; REMISSION INDUCTION; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 34547201150     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.22779     Document Type: Article

References (49)

1. Lowenberg B, Downing JR, Burnett A. Acute myeloid leukemia. N Engl J Med. 1999;341:1051-1062.
2. Aul C, Giagounidis A, Germing U, et al. Evaluating the prognosis of patients with myelodysplastic syndromes. Ann Hematol. 2002;81:485-497.
3. Menzin J, Lang K, Earle CC, et al. The outcomes and costs of acute myeloid leukemia among the elderly. Arch Intern Med. 2002;162:1597-1603.
4. Behringer B, Pitako JA, Kunzmann R, et al. Prognosis of older patients with acute myeloid leukemia receiving either induction or noncurative treatment: a single center retrospective study. Ann Hematol. 2003;82:381-389.
5. Goldstone AH, Burnett AK, Wheatley K, et al. Medical Research Council Adult Leukemia Working Party. Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial. Blood. 2001;98:1302-1311.
6. Rowe JM. Treatment of acute myelogenous leukemia in older adults. Leukemia. 2000;14:480-487.
7. Frohling S, Schlenk RF, Kayser S, et al. Cytogenetics and age are major determinants of outcome in intensively treated acute myeloid leukemia patients older than 60 years: results from AMLSG trial AML HD98-B. Blood. 2006;108:3280-3288.
8. Leith CP, Kopecky KJ, Godwin J, et al. Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. Blood. 1997;89:3323-3329.
9. Rossi G, Pelizzari AM, Bellotti D, et al. Cytogenetic analogy between myelodysplastic syndrome and acute myeloid leukemia of elderly patients. Leukemia. 2000;14:636-641.
10. Taylorfsfa P, Bown N, Cuthbert G, et al. A population based study of de-novo AML to assess karyotype incidence pattern and its impact on survival by age cohorts. Ann Haematol. 2001;80:S19.
11. Bennett JM, Catovsky D, Daniel MT, et al. Proposed revised criteria for the classification of acute myeloid leukemia: a report of the French-America-British Co-operative Group. Ann Intern Med. 1985;103:620-625.
12. Bennett JM, Catovsky D, Daniel MT, et al. The French-America-British Co-operative Group: proposals for classification of the myelodysplastic syndromes. Br J Haematol. 1982;51:189-199.
13. Mitelman F. ISCN: An International System for Human Cytogenetic Nomenclature. Basel: S. Karger; 1995.
14. Cheson BD, Bennett JM, Kantarjian H, et al. Report of an International Working Group to standardize response criteria for myelodysplastic syndromes. Blood. 2000;96:3671-3674.
15. Cheson BD, Cassileth PA, Head DR, et al. Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. J Clin Oncol. 1990;8:813-819.
16. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966;50:163-170.
17. Snedecar GW, Cochran WB. Statistical Methods. 6th ed. Ames: Iowa State University Press; 1967.
18. Cox DR. Regression models and life tables. J R Stat Soc. 1972;34:187-220.
19. Berman E, Heller G, Santorsa J, et al. Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia. Blood. 1991;77:1666-1674.
20. Lowenberg B, Zittoun R, Kerkhofs H, et al. On the value of intensive remission-induction therapy in elderly patients of 65+ years with acute myeloid leukemia: a randomized phase III study of the European Organization for Research and Treatment of Cancer Leukemia Group. J Clin Oncol. 1989;7:1268-1274.
21. Tricot G, Boogaerts MA. The role of aggressive chemotherapy in the treatment of the myelodysplastic syndromes. Br J Haematol. 1986;63:477-483.
22. Fenaux P, Morel P, Rose C, et al. Prognostic factors in adult de novo myelodysplastic syndromes treated by intensive chemotherapy. Br J Haematol. 1991;77:497-501.
23. Hamblin TJ. Intensive chemotherapy in myelodysplastic syndromes. Blood Rev. 1992;6:215-219.
24. Kern W, Haferlach T, Schoch C, et al. Early blast clearance by remission induction therapy is a major independent prognostic factor for both achievement of complete remission and long-term outcome in acute myeloid leukemia: data from the German AML Cooperative Group (AMLCG) 1992 trial. Blood. 2001;101:64-70.
25. Byrd JC, Mrozek K, Dodge RK, et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood. 2002;100:4325-4336.
26. Bloomfield CD, Goldman A, Hassfeld D, et al. Fourth International Workshop on Chromosomes in Leukemia 1982: clinical significance of chromosomal abnormalities in acute nonlymphoblastic leukemia. Cancer Genet Cytogenet. 1984;11:332-350.
27. Arthur DC, Berger R, Golomb HM, et al. The clinical significance of karyotype in acute myelogenous leukemia. Cancer Genet Cytogenet. 1989;40:203-216.
28. Fenaux P, Preudhomme C, Lai JL, et al. Cytogenetics and their prognostic value in de novo acute myeloid leukaemia: a report on 283 cases. Br J Haematol. 1989;73:61-67.
29. Schiffer CA, Lee EJ, Tomiyasu T, et al. Prognostic impact of cytogenetic abnormalities in patients with de novo acute nonlymphocytic leukemia. Blood. 1989;73:263-270.
30. Stasi R, Del Poeta G, Masi M, et al. Incidence of chromosome abnormalities and clinical significance of karyotype in de novo acute myeloid leukemia. Cancer Genet Cytogenet. 1993;67:28-34.
31. Dastugue N, Payen C, Lafage-Pochitaloff M, et al. Prognostic significance of karyotype in de novo adult acute myeloid leukemia. The BGMT Group. Leukemia. 1995;9:1491-1498.
32. Bloomfield CD, Lawrence D, Byrd JC, et al. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. Cancer Res. 1998;58:4173-4179.
33. Grimwade D, Walker H, Oliver F, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood. 1998;92:2322-2333.
34. Slovak ML, Kopecky KJ, Cassileth PA, et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group study. Blood. 2000;96:4075-4083.
35. Mrozek K, Heinonen K, Bloomfield CD. Clinical importance of cytogenetics in acute myeloid leukaemia. Best Pract Res Clin Haematol. 2001;14:19-47.
36. Grimwade D, Walker H, Harrison G, et al. The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood. 2001;98:1312-1320.
37. Keating MJ, Smith TL, Gehan FA, et al. Factors related to length of complete remission in adult acute leukemia. Cancer. 1980;45:2017-2029.
38. Norgaard JM, Olesen G, Kristensen JS, et al. Leukaemia cell drug resistance and prognostic factors in AML. Eur J Haematol. 1999;63:219-224.
39. Jackson GH, Taylor PR. Acute myeloid leukaemia: optimising treatment in elderly patients. Drugs Aging. 2002;19:571-581.
40. Fiegl M, Buchner T, Hiddemann W, et al. A phase I/II study of oral etoposide and idarubicin in elderly patients with high-risk acute myeloid leukemia unable to undergo intensive chemotherapy. Ann Hematol. 2005;84:227-231.
41. Schmelz K, Sattler N, Wagner M, et al. Induction of gene expression by 5-Aza-2′-deoxycytidine in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) but not epithelial cells by DNA-methylation-dependent and -independent mechanisms. Leukemia. 2005;19:103-111.
42. Ruter B, Wijermans PW, Lubbert M. DNA methylation as a therapeutic target in hematologic disorders: recent results in older patients with myelodysplasia and acute myeloid leukemia. Int J Hematol. 2004;80:128-135.
43. Issa JP, Garcia-Manero G, Giles FJ, et al. Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-Aza-2′- deoxycytidine (decitabine) in hematopoietic malignancies. Blood. 2004;103:1635-1540.
44. Gryn J, Zeigler ZR, Shadduck RK, et al. Treatment of myelodysplastic syndromes with 5-azacytidine. Leuk Res. 2002;26:893-897.
45. Silverman LR, Demakos EP, Peterson BL, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the Cancer and Leukemia Group B. J Clin Oncol. 2002;20:2429-2440.
46. Kuendgen A, Strupp C, Aivado M, et al. Treatment of myelodysplastic syndromes with valproic acid alone or in combination with all-trans retinoic acid. Blood. 2004:104:1266-1269.
47. Ferrara FF, Fazi F, Bianchini A, et al. Histone deacetylase-targeted treatment restores retinoic acid signaling and differentiation in acute myeloid leukemia. Cancer Res. 2001;61:2-7.
48. Phiel CJ, Zhang F, Huang EY, et al. Histone deacetylase is a direct target of valproid acid, a potent anticonvulsant, mood stabilizer and teratogen. J Biol Chem. 2001;276:36734-36741.
49. Gottlicher M, Minucci S, Zhu P, et al. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J. 2001;20:6969-6978.